Results 101 to 110 of about 24,516 (282)

Tocilizumab provides a potential therapeutic option for the management of hyperhaemolysis syndrome in sickle cell disease: A case series and brief narrative overview of the literature

Transfusion Medicine, EarlyView.
Abstract Background and Objectives Hyperhaemolysis syndrome is a life‐threatening complication of transfusion, potentially triggered by macrophage activation, with limited treatment options. Tocilizumab, an anti‐IL6 monoclonal antibody, has mechanistic rationale for use and has been shown to be effective in a small number of cases.
S. Wolf, B. Singh, A. Zaidi, P. Greaves, F. Oyesanya, S. Bennett, B. Kaya, F. Barroso, P. Telfer   +8 more
wiley   +1 more source

When the environment and mutations affect organ systems [PDF]

, 2017
Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy (TMA) with a genetic predisposition. Like other TMAs, it presents clinically with thrombocytopenia and microangiopathic hemolytic anemia, which is accompanied by disruption of
Abu Ghanimeh, Mouhanna, Abughanimeh, Omar, Qasem, Abdulraheem, Qasrawi, Ayman   +3 more
core   +1 more source

Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria

American journal of hematology/oncology
ABP 959 is a biosimilar to the eculizumab reference product (RP), which is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).
A. Kulasekararaj, F. Lanza, A. Arvanitakis, Saskia M C Langemeijer, S. Chonat, Anıl Tombak, V. Hanes, Jia Cao, Mieke Jill Miller, Alexander Colbert, Benjamin Shander, D. T. Mytych, V. Chow, H. Henary   +13 more
semanticscholar   +1 more source

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension [PDF]

, 2021
Sean J. Pittock, Kazuo Fujihara, Jacqueline Palace, Achim Berthele, Ho Jin Kim, Celia Oreja‐Guevara, Ichiro Nakashima, Michael Levy, Shulian Shang, Marcus Yountz, Larisa Miller, Róisín Armstrong, Dean M. Wingerchuk, the PREVENT Study Group   +13 more
openalex   +1 more source

Characterizing Perinatal Treatment Patterns and Outcomes in Myasthenia Gravis

Muscle &Nerve, Volume 73, Issue 2, Page 269-276, February 2026.
ABSTRACT Introduction/Aims Studies on pregnancy in myasthenia gravis (MG) are limited by small sample sizes or examine a limited number of outcomes. The objective of this study was to estimate the prevalence of perinatal and infant outcomes and characterize perinatal treatment patterns in MG.
Melanie H. Jacobson, Rupa Makadia, Ashley E. L. Anderson, Zia Choudhry, Nathan Hall, Jill Hardin, Sicong Huang, Janice M. Massey, Anna Ostropolets, Ran Sun, Rebecca Zaha, Alexis A. Krumme   +11 more
wiley   +1 more source

Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017). [PDF]

, 2019
BACKGROUND: To describe patients with inherited and acquired complement deficiency who developed invasive meningococcal disease (IMD) in England over the last decade. METHODS: Public Health England conducts enhanced surveillance of IMD in England.
Bai, X, Borrow, R, Campbell, H, Clark, SA, Gray, S, Ladhani, SN, Lekshmi, A, Lucidarme, J, Parikh, S, Patel, S, Ramsay, M, Walker, A, Willerton, L   +12 more
core   +1 more source

Impact of Prior Intravenous Immunoglobulin and Plasmapheresis on Eculizumab or Ravulizumab Treatment for Generalized Myasthenia Gravis: An Analysis of the MG SPOTLIGHT Registry

Clinical and Experimental Neuroimmunology, Volume 17, Issue 1, February 2026.
ABSTRACT Objective The complement component 5 inhibitor therapies (C5ITs) eculizumab and ravulizumab are approved for the treatment of generalized myasthenia gravis (gMG). We evaluated the real‐world effectiveness and safety of eculizumab and ravulizumab in patients with gMG with or without prior intravenous immunoglobulin (IVIg) or plasma exchange ...
Akiyuki Uzawa, Ema Rodrigues, Hiroyuki Murai   +2 more
wiley   +1 more source

Impact of Symptoms of Neuromyelitis Optica Spectrum Disorder and Patient‐Determined Oral Glucocorticoid–Related Adverse Events on Patients' Daily Living and Emotions: A Qualitative Analysis From Japan

Clinical and Experimental Neuroimmunology, Volume 17, Issue 1, February 2026.
ABSTRACT Background and Objectives Neuromyelitis optica spectrum disorder (NMOSD) is a chronic disorder with a relapsing–remitting disease course that impacts patients' quality of life. Oral glucocorticoids (OGCs) have been the standard of care for NMOSD in Japan; however, their chronic use is associated with adverse events (AEs).
Yuko Shimizu, Ichiro Nakashima, Ryotaro Ikeguchi, Tadashi Nagatsuka, Katsuhisa Yamashita, Yuta Fukuoka, Tatsunori Murata, Kazuo Fujihara   +7 more
wiley   +1 more source

1‐Year Clinical Outcome Post‐Myasthenic Crisis: A Multicenter Prospective Study in China

European Journal of Neurology, Volume 33, Issue 2, February 2026.
In this prospective cohort of 282 patients with myasthenic crisis (MC) episodes, all‐cause mortality was 15.16%. Among 247 patients who have completed 1‐year follow‐up, 79.76% achieved favorable outcomes with significant improvement in the MG‐activities of daily living (MG‐ADL) score.
Xiao Huan, Ran Chen, Lei Jin, Yuan Wang, Yafang Xu, Lei Yang, Caihua Xi, Jianming Zheng, Lijun Luo, Song Yang, Jianquan Shi, Yanping Liu, Zhe Ruan, Wanlong Wu, Wei Li, Yaoxian Yue, Yarong Li, Wenji Jia, Huahua Zhong, Chong Yan, Jie Song, Jianying Xi, Song Tan, Qilong Jiang, Zhangyu Zou, Chongbo Zhao, Sushan Luo, on behalf of the Chinese Myasthenia Gravis Collaborating Group (CMGCG), Yuzhou Guan, Yuwei Da, Huan Yang, Ting Chang, Yuge Wang, Bitao Bu, Hongyu Zhou, Chunsheng Yang, Hua Zhang, Hui Deng, Ruisheng Duan   +38 more
wiley   +1 more source

Cholesterol crystal-induced endothelial cell activation is complement-dependent and mediated by TNF [PDF]

, 2016
Cholesterol crystals are known to be a hallmark of atherosclerosis with recent studies demonstrating deposition of these crystals in early fatty streak formation as well as penetrating the intima following plaque rupture.
Espevik, Terje, Mollnes, Tom Eirik, Niyonzima, Nathalie, Nymo, Stig Haugset   +3 more
core   +3 more sources